The article discusses the decreased recruitment of eligible hospitalized patients with coronavirus disease (COVID-19) into randomized controlled trials (RCTs). Topics include the discovery of effective vaccines, therapies for COVID-19; extensions of need for successful trial, and increased refusal of COVID-19 RCT consent.